• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.

作者信息

Esfahani Khashayar, Hudson Marie, Batist Gerald

机构信息

McGill University, Montreal, QC, Canada

出版信息

N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527.

DOI:10.1056/NEJMc2002527
PMID:32521140
Abstract
摘要

相似文献

1
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.托法替布用于治疗PD-1治疗引起的难治性免疫相关性结肠炎。
N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527.
2
Efficacy of tofacitinib treatment in ulcerative colitis.托法替布治疗溃疡性结肠炎的疗效。
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.
3
Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.托法替布诱导疗法快速起效治疗溃疡性结肠炎
Clin Gastroenterol Hepatol. 2019 May;17(6):1213. doi: 10.1016/j.cgh.2018.11.038.
4
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.托法替布治疗溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
5
IBD: Tofacitinib effective in ulcerative colitis.炎症性肠病：托法替布对溃疡性结肠炎有效。
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):388. doi: 10.1038/nrgastro.2017.66. Epub 2017 May 17.
6
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?社论：托法替布与生物制剂治疗中重度溃疡性结肠炎——哪一种是同类最佳？
Aliment Pharmacol Ther. 2018 Feb;47(4):539-540. doi: 10.1111/apt.14480.
7
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.维多珠单抗与托法替布联合治疗一名溃疡性结肠炎合并脊柱关节炎患者
Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13.
8
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.社论：托法替布与生物制剂治疗中重度溃疡性结肠炎——哪一种堪称同类最佳？作者回复。
Aliment Pharmacol Ther. 2018 Feb;47(4):540-541. doi: 10.1111/apt.14486.
9
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.托法替布用于治疗对抗肿瘤坏死因子和抗整合素疗法难治的溃疡性结肠炎
Arq Gastroenterol. 2018 Apr-Jun;55(2):198-200. doi: 10.1590/S0004-2803.201800000-36.
10
Tofacitinib for the treatment of ulcerative colitis.托法替尼治疗溃疡性结肠炎。
Expert Rev Clin Immunol. 2018 Nov;14(11):881-892. doi: 10.1080/1744666X.2018.1532291. Epub 2018 Oct 11.

引用本文的文献

1
From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs.从创新到并发症：一例免疫检查点抑制剂诱发免疫相关性结肠炎的病例报告及文献复习
Pharmaceuticals (Basel). 2025 Aug 15;18(8):1211. doi: 10.3390/ph18081211.
2
Interferons in health and disease.健康与疾病中的干扰素
Cell. 2025 Aug 21;188(17):4480-4504. doi: 10.1016/j.cell.2025.06.044.
3
Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.晚期鳞状细胞癌的管理：皮肤科临床医生指南
J Clin Aesthet Dermatol. 2025 Aug;18(8):20-26.
4
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy.实体瘤接受免疫治疗患者胃肠道（GI）免疫相关不良事件的缓解策略。
Immunotherapy. 2025 Jun;17(8):595-603. doi: 10.1080/1750743X.2025.2516995. Epub 2025 Jun 6.
5
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.免疫检查点抑制剂治疗相关的胃肠道毒性：风险与管理
Immunotherapy. 2025 Mar;17(4):293-303. doi: 10.1080/1750743X.2025.2473305. Epub 2025 Mar 7.
6
JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune-Related Colitis Triggered by CTLA-4 and PD-1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report.JAK 抑制剂乌帕替尼诱导恶性胸膜间皮瘤中 CTLA-4 和 PD-1 抑制剂联合治疗引发难治性免疫相关性结肠炎缓解：病例报告。
Cancer Rep (Hoboken). 2024 Oct;7(10):e70032. doi: 10.1002/cnr2.70032.
7
Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.托法替布治疗癌症免疫治疗相关免疫不良事件的多中心观察性研究。
J Transl Med. 2024 Aug 29;22(1):803. doi: 10.1186/s12967-024-05617-6.
8
The Roles of T cells in Immune Checkpoint Inhibitor-Induced Arthritis.T细胞在免疫检查点抑制剂诱导的关节炎中的作用。
Aging Dis. 2024 Jul 26;16(4):2100-2119. doi: 10.14336/AD.2024.0546.
9
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.检查点抑制剂诱导的自身免疫性糖尿病：一种自身炎症性疾病。
Cold Spring Harb Perspect Med. 2025 Apr 1;15(4):a041603. doi: 10.1101/cshperspect.a041603.
10
Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis.托法替布用于治疗难治性免疫检查点抑制剂相关免疫性肾炎。
Clin Kidney J. 2024 Apr 25;17(5):sfae127. doi: 10.1093/ckj/sfae127. eCollection 2024 May.